Please provide your email address to receive an email when new articles are posted on . Statin therapy was tied to a 5-year CVD risk reduction in adults aged 75 years and older. Statin use did not ...

Patients with statin resistance do not experience symptoms, Le noted. Instead, the problem is that statins do not lower LDL-C levels as much as they typically do. Instead of a 50% reduction, people ...

Please provide your email address to receive an email when new articles are posted on . Black and Hispanic adults are less likely to use statins compared with white adults. Having health insurance or ...

(UPDATED) A new analysis is challenging the use of statin therapy for the primary prevention of cardiovascular disease, with researchers arguing that the lipid-lowering drugs should be more carefully ...

The number of patients taking statins for primary prevention has increased in the United States over the past two decades, but the percentage of eligible patients on treatment has appeared to plateau ...

These recommendations apply only to individuals without a history of CVD and who are not already taking statins. The US Preventive Services Task Force (USPSTF) has issued final recommendations on the ...

Future Cardiol. 2009;5(1):1-4. That leaves extrapolation from secondary prevention women's results to support primary prevention statin use, yet the risk profiles for women in the two groups obviously ...

HealthDay News — Statin use is associated with a significantly lower risk of mortality in older male physicians, and a non-significant lower risk of cardiovascular disease (CVD) events, according to a ...

Statins are associated with a small increased risk of side effects in patients without a history of heart disease, but these effects are mild compared with the potential benefits of treatment in ...

DALLAS, TX (updated) – Women, even those without evidence of atherosclerotic cardiovascular disease, should be treated with statin therapy if their baseline risk justifies use, according to one expert ...

SAN DIEGO -- Bempedoic acid (Nexletol) prevented cardiovascular events in high-risk, statin-intolerant patients who had not yet had an event, a subgroup analysis from the CLEAR Outcomes trial ...